(Q38081243)

28 August 2017

title

Chemotherapy regimens in early breast cancer: major controversies and future outlook (English)

1 reference

28 August 2017

Markus Joerger

1

1 reference

28 August 2017

Beat Thürlimann

series ordinal

2

1 reference

28 August 2017

publication date

1 February 2013

1 reference

Expert Review of Anticancer Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

165-178

1 reference

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol I

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

HER2/neu in systemic therapy for women with breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Role of anthracyclines in the treatment of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAK

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Molecular classification of estrogen receptor-positive/luminal breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Gene-expression profiling and the future of adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Clinical application of the 70-gene profile: the MINDACT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Dissecting the heterogeneity of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.172

21 January 2018

Identifiers

DOI

10.1586/ERA.12.172

1 reference

28 August 2017

1 reference